Tilray | TRLY - Operating Profit

Stock Price
7.28
Daily Change
-0.26 -3.45%
Monthly
-22.22%
Yearly
970.59%
Q2 Forecast
7.13

Tilray reported $-20.01M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acasti Pharma USD -2.53M 560K Sep/2025
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Aurora Cannabis CAD -35.79M 19.88M Dec/2025
Avita Medical AUD -10.41M 742K Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Cronos Group USD -1.45M 5.61M Mar/2026
Dianthus Therapeutics USD -69.54M 29.25M Dec/2025
Divis Laboratories Ltd INR 7.72B 30M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Organigram Holdings CAD -20.13M 7.92M Dec/2025
Organon & Co USD 217M 171M Dec/2025
Revvity USD 82.77M 63.06M Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 16.77M 10.04M Dec/2025
Zealand Pharma A/S -707.05M 245.73M Dec/2025